A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 May 2016 Results of comparison of overall survival data for ipilimumab, vemurafenib and dacarbazine from three trials including this published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
    • 07 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 24 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top